← FDA DRUG APPROVALS

FDA ANDA · ANDA206851

SIMPESSE

levonorgestrel and ethinyl estradiol and ethinyl estradiol

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA206851
TYPE
ANDA
ORIGINAL APPROVAL
2017-04-07
LATEST ACTION
2025-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SIMPESSEPrescription
ETHINYL ESTRADIOL 0.03MG,0.01MG, LEVONORGESTREL 0.15MG,N/A · TABLET · ORAL

Approval history

2025-06-18Labeling · Supplement 4 · standardAP
2023-01-20Labeling · Supplement 2 · standardAP
2023-01-20Labeling · Supplement 3 · standardAP
2023-01-20Labeling · Supplement 1 · standardAP
2017-04-07UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →